Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Gynecologic Oncology|May 29, 2018
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancerCarol Aghajanian, Virginia Filiaci, Don S Dizon, et al.
Gynecologic Oncology|March 19, 2017
FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group studyYvette W Jeske, Shamshad Ali, Sara A Byron, et al.
JAMA Oncology|December 16, 2017
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical TrialDebra L Richardson, Michael W Sill, Robert L Coleman, et al.
Gynecologic Oncology|January 17, 2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group studyVivian E von Gruenigen, Helen Q Huang, Jan H Beumer, et al.
Gynecologic Oncology|March 26, 2017
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group studyDanielle A Jandial, William E Brady, Stephen B Howell, et al.
Gynecologic Oncology|October 4, 2017
Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group studyEric J Devor, Jeffrey Miecznikowski, Brandon M Schickling, et al.
Gynecologic Oncology|March 5, 2019
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group studyRebecca A Brooks, David S Tritchler, Kathleen M Darcy, et al.
JAMA Oncology|January 1, 2016
Inherited Mutations in Women With Ovarian CarcinomaBarbara M Norquist, Maria I Harrell, Mark F Brady, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2021
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular ResponseLinda R Duska, Virginia L Filiaci, Joan L Walker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyD Scott McMeekin, David L Tritchler, David E Cohn, et al.
Pageof 7